New manufacturing process increases the final yield of nomacopan by at least 5-fold thereby significantly lowering the cost of goods for clinical studies and …
Akari Therapeutics to Present at H.C. Wainwright BioConnect Virtual Conference
NEW YORK and LONDON, January 4, 2022 – Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to …
[Read more...] about Akari Therapeutics to Present at H.C. Wainwright BioConnect Virtual Conference
Akari Therapeutics, Plc Announces $6.0 Million Registered Direct Offering
NEW YORK and LONDON, December 30, 2021 – Akari Therapeutics, Plc (Nasdaq: AKTX) (“Akari” or the “Company”), a biopharmaceutical company focused on innovative …
[Read more...] about Akari Therapeutics, Plc Announces $6.0 Million Registered Direct Offering
Akari Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Clinical Progress
Sites opened in Phase III study of nomacopan in bullous pemphigoid (BP)Phase III study of nomacopan in severe pediatric hematopoietic stem cell …
Akari Therapeutics Presents New Data Revealing Potential Mechanism of Action Driving Serious Exacerbations Across Lung Disorders
Data suggest potential therapeutic role for nomacopan in exacerbations in severe lung conditions such as COPD and COVID pneumonia NEW YORK and LONDON, …
